glp 1 agonist approved for weight loss The New Management Meds Comparing GLP-type therapies for weight

The best results happen when the medicine is used along with healthy eating and exercise, and people may gain weight back if they stop taking the medicine

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

Although rare, associations with nonarteritic anterior ischemic optic neuropathy, pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported, primarily through pharmacovigilance and case-based evidence

Arizona OPEN ACCESS PUBLISHED:30 October 2024 CITATION:Chakkera, S

What Is A GLP-1 Agonist

This Comment highlights emerging evidence and advocates for clinical strategies that prioritize muscle preservation to ensure the long-term success and safety of pharmacological weight management.